Free Trial
NASDAQ:ZURA

Zura Bio Q4 2024 Earnings Report

Zura Bio logo
$1.13 +0.02 (+1.80%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.19 +0.06 (+5.66%)
As of 06/20/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Zura Bio Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zura Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zura Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Zura Bio Earnings Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA), a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

View Zura Bio Profile

More Earnings Resources from MarketBeat